Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 13 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 11504426

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  2. US 11498970

    Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  3. US 11498969

    Compositions and methods for treating juvenile idiopathic arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  4. US 11492392

    Polynucleotides encoding anti-C5 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  5. US 11491237

    Cyclodextrin protein drug conjugates

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  6. US 11491222

    Method of treating lower back pain

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  7. US 11485958

    HSD17B13 variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  8. US 11485793

    Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  9. US 11485788

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  10. US 11485770

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  11. US 11479602

    Methods of treating C5-associated diseases comprising administering anti-C5 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  12. US 11472870

    Pharmaceutical composition for safe and effective treatment of knee and/or hip pain

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  13. US 11472861

    Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  14. US 11464830

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  15. US 11459374

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  16. US 11459373

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  17. US 11453721

    Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  18. US 11453714

    Human antibodies to influenza hemagglutinin

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  19. US 11446389

    Maytansinoid derivatives, conjugates thereof, and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted
  20. US 11440950

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  21. US 11439683

    Anti-angiogenic therapy of metastatic colorectal cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  22. US 11434300

    Methods and antibody compositions for tumor treatment

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  23. US 11421036

    Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  24. US 11419318

    Genetically modified rat comprising a humanized TRKB locus

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted